Hepatocyte SLAMF3 reduced specifically the multi-drugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2016

Hepatocyte SLAMF3 reduced specifically the multi-drugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs

Jean-Marc Regimbeau

Résumé

Multidrug resistance MDR proteins (MRPs) are members of the C family of a group of proteins named ATP binding cassette (ABC) transporters. MRPs can transport drugs including anticancer drugs, nucleoside analogs, antimetabolites and tyrosine kinase inhibitors. Drugs used in HCC therapy, such as tyrosine kinase inhibitor sorafenib, are substrates of uptake and/or efflux transporters. Variable expression of MRPs at the plasma membrane of tumor cells may contribute to drug resistance and subsequent clinical response. Recently, we reported that the hepatocyte SLAMF3 expression (Signaling Lymphocytic Activation Molecule Family member 3) was reduced in tumor cells from hepatocellular carcinoma (HCC) compared to its high expression in adjacent tissues. In the present study, we make a strong correlation between induced SLAMF3 overexpression and the specific loss of MRP-1 expression and its functionalities as a drugs resistance transporter. No changes were observed on expression of ABCG2 and MDR. More importantly, we highlight a strong inverse correlation between MRP-1 and SLAMF3 expression in patients with HCC. We propose that the SLAMF3 overexpression in cancerous cells could represent a potential therapeutic strategy to improve the drugs sensibility of resistant cells and thus control the therapeutic failure in HCC patients.

Dates et versions

hal-03589642 , version 1 (25-02-2022)

Identifiants

Citer

Gregory Fouquet, Véronique Debuysscher, Hakim Ouled-Haddou, Melanie Simoes Eugenio, Baptiste Demey, et al.. Hepatocyte SLAMF3 reduced specifically the multi-drugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. Oncotarget, 2016, 7 (22), pp.32493-32503. ⟨10.18632/oncotarget.8679⟩. ⟨hal-03589642⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More